Caprotec Bioanalytics
Wilmington
About Caprotec Bioanalytics
caprotec bioanalytics has developed a ground-breaking, proprietary technology to reduce the complexity of protein mixtures and samples in a targeted and directed manner. caprotec's Capture Compound Mass Spectrometry (CCMS) Technology is based on multifunctional small molecules (Capture Compounds™) that are used to target, capture, and isolate proteins based on their functionality. For many applications, CCMS is clearly superior to shotgun approaches - thus addressing an unmet need in the proteomics community.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $23.5M
- Funding stage: M&A
- Last round: Series B (May 2011)
- Website: caprotec.com
- Phone: +1 781-222-6000
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/caprotec-bioanalytics-472981 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.